Shanghai Ancora Biotechnology Co., Ltd.

Shanghai Ancora Biotechnology Co., Ltd. is mainly engaged in biotechnology research, product development and industrialization, and is committed to and focused on high-throughput gene sequencing and its application in early cancer screening and precision treatment. Shanghai Yunsheng Medical Laboratory is a newly established independent third-party medical laboratory, which has set up two specialties: clinical immunology and serology, and clinical cell and molecular genetics.
Our independently developed and created Firefly technology is an ultra-high precision, ultra-high sensitivity circulating tumor gene high-throughput sequencing (ctDNA-NGS) technology, which has now developed into a new non-invasive molecular pathological diagnostic technology. It can obtain gene mutation information from solid tumor tissues by analyzing DNA fragments from tumor cells in plasma at any time point, truly realizing "liquid biopsy" of tumors. This technology can be used not only for "precision medicine" for tumor patients, but also can be developed into a new method of medical auxiliary diagnosis for early screening, early detection and early diagnosis of tumors.
The company will gradually form an industrial system oriented by the Chinese market and supported by innovative technology and continuous research and development, gradually develop into a world-class enterprise for tumor gene sequencing and analysis and its clinical application both domestically and internationally, and rapidly transform innovative technologies into products and service capabilities, providing urgently needed innovative diagnostic and therapeutic technologies for the majority of tumor patients and high-risk groups.
We use our medical laboratory and CLIA laboratory as service platforms to carry out scientific research and clinical testing in China and the United States respectively, aiming to practice the corporate mission of "Anren, Anji, Kejicangsheng".